Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability and PK of ENERGI-F705 in Healthy Volunteers
NCT07650383Phase 1Completed
- Sponsor
- Energenesis Biomedical Co., Ltd.
- Start
- Feb 2025
- Primary completion
- May 2025
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ENERGI-F705 (3 arms), sponsored by Energenesis Biomedical Co., Ltd. Primary endpoint: Treatment-Emergent Adverse Events at 4 days. Started Feb 2025; status: completed.
02
Drugs
ENERGI-F705
Beyond the preview
Go deeper on NCT07650383.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07650383.